Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Small Cell Lung Carcinoma 1Leukemia, Myeloid, Acute 1Congenital Abnormalities 1Carcinoma, Small Cell 1Carcinoma, Neuroendocrine 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 7fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 6Mycophenolic Acid 5Whole-Body Irradiation 4Filgrastim 4fludarabine 3Cytarabine 3Cyclosporine 3Cord Blood Stem Cell Transplantation 3Busulfan 3Transplantation 2Topotecan 2Tacrolimus 2Gene Expression Profiling 2Flow Cytometry 2Etoposide 2Cytogenetic Analysis 2Bone Marrow Transplantation 2Azacitidine 2tipifarnib 1sargramostim 1pegylated granulocyte colony-stimulating factor 1montanide ISA 51 1decitabine and cedazuridine drug combination 1aldesleukin 1X-Rays 1Vorinostat 1Vitamin E 1Tretinoin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Anemia, Refractory, with Excess of Blasts × Podophyllotoxin × Clear all
NCT00540995 2023-11-30

Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer

City of Hope Medical Center

Phase 1/2 Terminated
25 enrolled 9 charts
Classical hematologyOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Blast Crisis, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡